

1 COOLEY GODWARD LLP
2 STEPHEN P. SWINTON (106398)
3 J. CHRISTOPHER JACZKO (149317)
4 4365 Executive Drive, Suite 1100
5 San Diego, California 92121-2128
6 Telephone: (858) 550-6000
7 Facsimile: (858) 453-3555

8 DOUGLAS E. OLSON (38649)
9 BROBECK, PHLEGER & HARRISON LLP
10 12390 El Camino Real
11 San Diego, California 92130-2081
12 Telephone: (858) 720-2500
13 Facsimile: (858) 720-2555

14 R. WILLIAM BOWEN, JR. (102178)
15 GEN-PROBE INCORPORATED
16 10210 Genetic Center Drive
17 San Diego, California 92121-4362
18 Telephone: (858) 410-8918
19 Facsimile: (858) 410-8637

20 Attorneys for Plaintiff
21 Gen-Probe Incorporated

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2029
2030
2031
2032
2033
2034
2035
2036
2037<br

I, Joseph O. Falkingham, III, hereby declare as follows:

1. I have personal knowledge of the facts set forth below, and, if called as a witness in this action, I could and would testify competently to the truth thereof.

2. As disclosed in my *Curriculum Vitae* attached hereto as Exhibit 1, I received an A.B. (Bacteriology, 1964) and a Ph.D. (Microbiology, 1969) from the University of California, Berkeley. I served in the United States Air Force Biomedical Sciences Corps directing hospital clinical laboratories from 1969 to 1972 and then accepted appointment as Fellow in Microbiology (postdoctoral fellowship) in the University of Alabama Medical Center (1972-1974). In 1974, I joined the faculty of Virginia Polytechnic Institute and State University. I have been a professor at Virginia Polytechnic Institute and State University for 26 years where, in addition to my teaching duties, I have been engaged extensively in molecular biological research. My research has focused on gene transmission mechanisms in the bacterium *Escherichia coli* (1964-1980) and on the epidemiology, ecology, physiology, and genetics of *Mycobacterium avium* (1975-present). I have published numerous research articles and book chapters, as well as directed numerous graduate student theses and dissertations in this general field.

3. Nucleic acid target capture and amplification are related to my fields of study, and I am familiar with both the non-specific methods of amplification disclosed by U.S. Patent No. 5,750,338 ("the '338 patent") and specific amplification techniques such Gen-Probe's Transcription-Mediated Amplification (TMA) system.

4. I have been retained as an expert witness in this lawsuit. I have reviewed the specification and claims of the '338 patent (Exhibit 8¹).

SUMMARY OF OPINION

5. It is my opinion that, as of December 21, 1987, a person of ordinary skill in the art would have understood the term "amplifying" as used in the claims of the '338 patent to mean amplifying any nucleic acid sequence present in a sample by use of the non-specific amplification methods described in the '338 specification. Reading the specification, a person of ordinary skill

¹ Unless otherwise specified, all references to Exhibits shall refer to the corresponding exhibit attached to the Notice of Lodgment of Exhibits filed concurrently herewith.

1 in the art would *not* have understood the term "amplifying" as used in the claims of the '338 patent
2 to mean amplifying by use of sequence-specific amplification methods incorporating specific
3 primers, specific promoters, and/or specific enzymes.

4 **BACKGROUND**

5 6. Several naturally occurring enzymes create copies of nucleic acids in the cells of
6 living organisms (i.e., "*in vivo*") in a process generally called "replication." These replication
7 enzymes include DNA polymerases, RNA polymerases, and transcriptases. Each of these
8 replication enzymes works by binding to a nucleic acid and producing a complementary copy of its
9 sequence. Some of these enzymes (e.g., DNA polymerases) require primers to initiate
10 replication.

11 7. Each replication enzyme is named for the reaction it catalyzes. For example,
12 a DNA polymerase catalyzes a reaction that produces a DNA polymer strand, while an RNA
13 polymerase catalyzes a reaction that produces an RNA polymer strand.

14 8. Procedures that amplify DNA in a laboratory are generally performed using
15 replication enzymes and primers, which are short pieces of DNA that bind to a portion of a nucleic
16 acid adjacent to the sequence to be amplified. Amplification takes place when the replication
17 enzymes are able to work in conjunction with the primers to make copies of a nucleic acid
18 sequence.

19 9. The primer is used to specify the portion of the nucleic acid that will be copied.
20 Primers bind to DNA if there are a sufficient number of complementary base pair matches. The
21 polymerase enzyme then uses the primer as the starting point for its copying action. Generally, in
22 laboratory amplification two primers are used to produce a copy of the sequence that occurs
23 *between* the two points where the primers bind to the target nucleic acid.

24 10. Like the primers used in the amplification process, the enzymes as well can be
25 specific or non-specific. Specific replication enzymes will only bind to a nucleic acid when the
26 enzyme recognizes a specific sequence of nucleotide bases. However, many of those same
27 enzymes can and have been modified by scientists, or used in particular reaction conditions (e.g.,
28 lower than normal salt concentrations), to remove this specific recognition aspect and make them

1 non-specific so that they can bind to and replicate a variety of different sequences.
2 11. Primers used in *specific* amplification procedures are selected to bind to a specific,
3 unique sequence in a particular organism's DNA, and no other organism's DNA. Such primers are
4 referred to as "specific" or "sequence-specific" primers. For example, the "Polymerase Chain
5 Reaction" or "PCR" method of amplification, invented by Dr. Kary Mullis and others at Cetus
6 Corporation in 1983, uses sequence-specific primers to amplify a specific nucleic acid sequence
7 that is between the two primers. That specific nucleic acid sequence may be contained within a
8 large collection of sequences, and the method thus defines a specific fragment of DNA to be
9 selectively amplified.

10 12. While primers are generally designed to be specific to a particular nucleic acid
11 target, it is also possible to produce "random" primers, which are mixtures of primers that contain
12 hundreds and thousands of random nucleotide sequences. These primers are usually collections of
13 short DNA fragments, averaging about 6 nucleotides in length. Short sequences that are
14 complementary to these so-called "random hexamers" occur frequently within virtually all nucleic
15 acids. Thus, they will bind at multiple points along any nucleic acid sequence to serve as initiation
16 sites for replication. The target nucleic acid sequence is replicated as a set of smaller fragments,
17 each beginning with the sequence of its initiating primer. Random hexamer primers have been
18 commercially available since the 1970's. By using "universal" or "random" primers in an
19 amplification process, it is possible to avoid the labor and cost that would be necessary in order to
20 develop specific primers for each target nucleic acid. The trade-off in using random primers is that
21 the amplification process will not be specific for the sequence of interest, and instead will amplify
22 any nucleic acid present in the sample (including sequences that are not of interest).

23 13. "Specific" primers and enzymes will function together to amplify a target nucleic
24 acid only if the specific sequence of interest bound by the primer(s) and/or recognized by the
25 enzyme is present in the sample. By contrast, non-specific primers and enzymes will amplify *any*
26 sequence present in the sample because some random primers will bind to the sequences in the
27 sample and non-specific replication enzymes will catalyze the reaction without regard to the
28 sequence.

1 **THE MEANING OF CLAIM TERMS IN VIEW OF THE '338 PATENT'S TEACHINGS**

2 14. The '338 patent describes combining target capture with *non-specific* amplification
3 of the captured nucleic acid sequence. By "non-specific amplification," I mean that the primers
4 described in the patent are not pre-selected to bind to specific nucleotide sequences as part of the
5 amplification process. The enzymes described in the patent are also non-specific and will cause
6 replication of any sequence. My opinion about the meaning of the term "amplifying" is based on
7 my understanding of the state of the art at the time the application for the '338 patent was filed and
8 the description of the invention set forth by the inventors in the '338 patent. I discuss the reasons
9 for my opinion below.

10 **Introduction to the Patent Specification**

11 15. In the "Background of the Invention" section, the patent defines the term "amplify"
12 in very broad terms that encompass many different methods of amplification, including many that
13 were already well-known in the art. Throughout the remainder of the specification, however, the
14 inventors teach only non-specific amplification, a subset of the methods known in 1987, because --
15 the inventors say -- a benefit of their invention is that it *eliminates* the need to design and prepare
16 specific primers and/or the need to use specific enzymes. [The '338 Patent at column 30, lines 30-
17 40.] Thus, the inventors intentionally teach the use of amplification methods that are significantly
18 more limited than the full range of amplification methods known in the art at the time. The
19 inventors' description of their invention narrowed the term "amplify," with respect to the
20 invention, from the general definition initially set forth in the "Background of the Invention."

21 **The Fundamental Teaching Of The '338 Patent**

22 16. The '338 patent presents seven examples of the methods taught by the inventors. In
23 the first three examples, the inventors refer only to methods of target capture, without an
24 amplification step. In the last four examples, the inventors teach combining a target capture step
25 with amplification methods.

26 17. Between the end of the target capture examples (Examples 1-3) and the first
27 example to add an amplification step (Example 4), the inventors expressly set forth their teachings
28 with respect to amplification methods. Referring to the target capture methods described in

1 Examples 1 through 3, the inventors stated:

2 The sensitivity of the above DNA or RNA target capture methods
3 can be enhanced by amplifying the captured nucleic acids. This can
4 be achieved by *nonspecific replication using standard enzymes*
(polymerases and/or transcriptases).

5 (*338 patent, Exh. 8, at col. 30, ll. 14-18, emphasis added.)

6 18. The inventors then stated *why* they had chosen to combine their target capture
7 methods with non-specific amplification. The inventors stated that the target capture step of their
8 method made specific amplification primers and enzymes unnecessary:

9 Amplification of the target nucleic acid sequences, because it
10 follows purification of the target sequences, can employ
11 *non-specific enzymes or primers... Thus no specifically tailored
primers are needed for each test, and the same standard reagents
can be used, regardless of targets.*

12 (*Id.* at col. 30, ll. 30-40, emphasis added.) A person skilled in the art as of December 1987 would
13 have understood from this description that a primary benefit of this invention was that it used
14 "standard" primers and reagents for all amplification reactions. A person skilled in the art would
15 have understood that, by using the method of the invention, one would not need to design and test
16 specific primers for each particular target organism and/or use other individualized reagents.
17 When the patent says that "no specifically tailored primers are needed ... and the same standard
18 reagents can be used, regardless of targets," one skilled in art would conclude that the invention
19 does not encompass methods of *specific* amplification. In fact, the inventors tell one of ordinary
20 skill in the art that there is no need for specific amplification using their method.

21 **The Drawings and Examples Of The Patent**

22 19. The first pages of the '338 patent provide drawings of various methods
23 encompassed by the invention. The drawings are discussed and described in sections in the
24 sections entitled "Brief Description of the Drawings" and "Detailed Description" ('338 Patent,
25 Exh. 8, at cols. 9-19.) The drawings are also referred to in the "Examples" set forth in the final
26 section of the specification, immediately preceding the claims (Columns 24-32).

27 ///

1 20. The first 3 drawings (Figure 1a to Figure 3) depict target capture methods alone,
2 without amplification. Figures 4, 5 and 6 depict a target capture step followed by an amplification
3 step using only non-specific primers or enzymes. The patent text expressly states that in each of
4 these drawings “the isolated target is *non-specifically* amplified to form a multitude of
5 amplification products.” (*Id.* at col. 15, ll. 56-58, emphasis added.)

6 21. In the “Examples” section of the patent, the inventors set forth seven examples to
7 further describe their invention (*Id.* at col. 24 to 32). As discussed above, the first three examples
8 describe target capture methods, without amplification. After Example 3, the inventors set forth
9 the fundamental teaching of the ‘338 patent with respect to the use non-specific amplification
10 (discussed in paragraphs 19 and 20 above). Then, the inventors present four examples of
11 amplification methods combined with target capture (Examples 4 - 7). Although these four
12 examples describe different amplification methods, all of those methods describe *non-specific*
13 amplification. Each of these examples is consistent with the earlier teaching of the patent that
14 sequence-specific primers and specific enzymes are not necessary.

15 22. The Drawings, associated text, and Examples do not describe methods that combine
16 target capture with sequence-specific amplification methods using specific primers or enzymes.
17 The absence of such references is consistent with the patent’s core teaching that the burden of
18 specific amplification methods can be avoided when the inventor’s methods are used.

19 **Figure 4 and Example 4**

20 23. Figure 4 and Example 4 of the ‘338 patent describe only a form of non-specific
21 amplification, namely, non-specific transcription.

22 24. In describing Figure 4, the patent states that the amplification reaction uses “core
23 RNA polymerase” to produce to produce a complementary RNA. (Col. 15, ll. 59-61; see also Fig.
24 4, Step 3). Core RNA polymerase lacks an accessory protein (the sigma protein) that endows the
25 core enzyme with the ability to bind to certain nucleotide sequences and initiate RNA synthesis
26 (Example 4, column 30, lines 59-66). The core RNA polymerase, lacking sigma protein, binds
27 anywhere on a DNA, thus producing a variety of complementary sequences (Figure 4, step 3, and
28 Example 4 (Col. 31, lines 5-16)). Thus, core RNA polymerase amplifies non-specifically by

1 transcribing² *any* sequence with which it comes into contact. Example 4 further states that other
2 "RNA polymerases that *lack transcriptional specificity...*" can be used in place of the particular
3 polymerase suggested by the inventors (Col. 30, line 66 to col. 31, line 1).

4 25. Figure 4 and Example 4 describe only non-specific amplification. Figure 4 and
5 Example 4 do not describe the use of sequence-specific primers or enzymes in the amplification
6 step. The method described by the inventors in Example 4 is consistent with their earlier teaching
7 that no specifically tailored primers are needed for each test, and the same standard reagents can be
8 used, regardless of targets.

9 **Figure 5 and Example 5**

10 26. Figure 5 and Example 5 describe a form of non-specific amplification in which the
11 isolated target DNA is non-specifically replicated and then non-specifically transcribed:

12 In this example, both *non-specific* replication of target DNA and
13 transcription of that DNA are used to amplify capture target DNA....
14 Because the primers are *random*, some will, simple (sic) as a matter
of statistics, bind to and cause replication of sample sequences, no
matter what those sequences are. . . .

15 (*338 Patent, Exh. 8, at col. 31, l. 24-54, emphasis added.)

16 27. In Figure 5, the inventors describe a "two enzyme amplification system" that uses,
17 first, in step 3(a), a DNA polymerase with random hexamer primers to make DNA strands, and
18 second, in step 3(b), core RNA polymerase to form additional RNA complements of the DNA
19 (Col. 16, ll. 10-16; Example 5, col. 31, lines 25-53). As previously set forth, core RNA
20 polymerase amplifies *non-specifically*.

21 28. Further, because of the limited number of primers of the same sequence in the
22 mixture of random hexamers, there would be little accumulation of specific sequences. The
23 primers become part of the amplified product and are thus consumed.

25 2 "Transcription" is a process of nucleic acid synthesis in which an RNA polymerase makes a
26 single-stranded RNA copy of a DNA strand. Transcription does not require primers. In non-
27 specific transcription, the RNA polymerase initiates synthesis randomly at multiple points along
28 the DNA. Specific transcription occurs when the RNA polymerase with sigma protein recognizes
and binds to a specific sequence in the DNA called a "promoter." The RNA is then synthesized
beginning at that point.

1 29. The "hexamer primers" and "random oligohexamer primers" described in Figure 5,
2 step 3a, and Example 5 (col. 31, lines 31-32) are commercially available pieces of DNA six bases
3 long, that are a collection of random nucleotide sequences (see col. 31, lines 32-33). The hexamer
4 primers and DNA polymerase depicted in Figure 5, step 3a, would indiscriminately replicate any
5 nucleic acid sequences present in the reaction mixture, which is explicitly stated in Example 5
6 ("non-specific replication of target DNA." (Col. 31, ll. 24-25, emphasis added.)) Thus, a family
7 of different sequences would be produced as a result of the non-specific amplification. Further,
8 because mixtures of random hexamers will vary, the products of non-specific amplification would
9 differ from individual experiment to experiment.

10 30. In the second enzyme step described in Figure 5, step 3b, and in Example 5, non-
11 specific RNA polymerase is added to non-specifically produce many RNA copies from the DNA.

12 31. Thus Figure 5 and Example 5 describe only non-specific amplification. The
13 inventors described and illustrated a method that is consistent with the teaching of the patent that
14 no specifically tailored primers are needed for each test, and that standard reagents can be used,
15 regardless of target nucleic acid.

16 **Figure 6 and Example 6**

17 32. Figure 6 and Example 6 describe only non-specific amplification of a "captured"
18 nucleic acid, using DNA polymerase and "non-specific" or "random hexamer primers" to bring
19 about non-specific double-stranded DNA synthesis (Figure 6, Step 3a; col. 16, lines 17-23;
20 Example 6, col. 31, lines 63-64).

21 33. The amplification process described in Example 6 and illustrated in Figure 6 is a
22 cycling method similar to the cycles of synthesis used in the PCR method, but the method
23 described in the '338 patent does not use sequence-specific primers. Instead, the method taught by
24 the inventors in the '338 patent describes the use of a target capture step to isolate the target
25 nucleic acid from other nucleic acids, followed by multiple cycles of DNA synthesis, each initiated
26 by using random hexamer (e.g., non-specific) primers. There would be no accumulation of
27 unique sequences, because of the consumption of primers during non-specific amplification.

1 34. Example 6 states that the amplification step described therein (and depicted in
2 Figure 6) uses DNA polymerase and “*random* hexamer oligonucleotides to bring about
3 *non-specific* double-stranded DNA synthesis” (‘338 Patent, Exh. 8, at col. 31, ll. 63-64, emphasis
4 added).

5 35. Thus Figure 6 and Example 6 describe only non-specific amplification. The
6 method described by the inventors in Example 6 is consistent with their teaching that no
7 specifically tailored primers are needed for each test, and the same standard reagents can be used,
8 regardless of the target sequence.

9 **Example 7**

10 36. In Example 7, the inventors describe another method of non-specific amplification.
11 (There is no drawing in the patent that depicts the method of Example 7.)

12 37. In Example 7, the inventors describe a *non-specific* amplification method that uses
13 an RNA polymerase, Q β replicase:

14 In this example, rRNA and RNA transcribed from target DNA is
15 purified using a capture probe, described above. The hybrid duplex
16 is then denatured and single stranded nucleic acids are then
replicated *non-specifically* using Q β replicase...

17 (‘338 Patent, Exh. 8, at col. 32, l. 10-19, emphasis added.)

18 38. Thus Example 7, like Examples 4, 5 and 6, also discloses only non-specific
19 amplification of a captured nucleic acid. This method is also consistent with the inventors'
20 teaching that the methods of their invention do not require specifically designed or predetermined
21 primers and that the same reagents and replicase can be used for each test, regardless of the target

22 **Procedures**

23 39. The ‘338 patent describes certain procedures to be used in connection with the
24 invention (columns 19-24).

25 40. In the “Procedures” section, the inventors did not prescribe any procedures for
26 designing, making, or using sequence-specific primers or enzymes, nor any procedures for
27 combining target capture with methods of specific amplification. This omission is consistent with
28 the teaching of the patent that specifically tailored primers are not needed for any test, and the

1 same standard reagents can be used.

2 **The Understanding of A Person of Ordinary Skill in the Art at the Time of Filing**

3 41. I understand that a term in a patent claim will be given the meaning that would have
4 been understood, based on the description provided by the inventors in the patent, by one of
5 ordinary skill in the art. I further understand that the meaning is determined as of the date on
6 which the first patent application was filed for the claimed invention. I have been informed that
7 the applicable date in this case is December 21, 1987.

8 42. A person of ordinary skill in the art in December 1987, reading the '338 patent
9 specification, would understand the term "amplifying" in the claims to mean using non-specific
10 amplification methods (such as those described and illustrated in the patent).

11 43. In the '339 patent, the inventors explicitly teach that the benefit of their invention is
12 that it allows the use of non-specific amplification. The inventors apparently believed that the
13 specificity of the target capture step of their method permitted scientists to avoid the need for
14 specific amplification:

15 The sensitivity of the above DNA or RNA target capture methods
16 can be enhanced by amplifying the captured nucleic acids. This can
17 be achieved by *nonspecific replication using standard enzymes*
(polymerases and/or transcriptases).

18 ('338 patent, Exh. 8, at col. 30, ll. 14-18, emphasis added.)

19 Amplification of the target nucleic acid sequences, because it
20 follows purification of the target sequences, can employ
21 *non-specific enzymes or primers... Thus no specifically tailored
primers are needed for each test, and the same standard reagents
can be used, regardless of targets.*

22 (*Id.* at col. 30, ll. 30-40, emphasis added.)

23 44. This express teaching of the patent is reinforced by the fact that the only
24 amplification methods that the inventors chose to describe and illustrate with Examples and
25 Drawings are non-specific amplification methods.

26 45. Further reinforcing my conclusion is the fact that PCR, the most commonly used
27 sequence-specific amplification method at the filing date, is not included, described or referenced
28 in the specification. Moreover, the specification does not contain a reference to any other
in the specification. Moreover, the specification does not contain a reference to any other

1 sequence-specific amplification method.

2 46. If the inventors had intended to suggest and claim the combination of target capture
3 with sequence-specific amplification methods such as PCR, it would have been easy for them to do
4 so. The PCR method was first described at a scientific meeting in the summer of 1985 and was
5 published in December 20, 1985. Within the scientific community, PCR was immediately
6 recognized as a significant improvement over earlier methods of making copies of nucleic acids,
7 and knowledge of the method was widespread.

8 47. Although the application leading to the '338 patent was filed two years after PCR
9 was publicly disclosed, the patent does not describe or teach a method that combines target capture
10 with amplification methods using specific primers, such as PCR.

11 48. Although the '338 inventors could have included an example in the patent that
12 combined target capture and sequence-specific amplification (such as PCR), the inventors instead
13 described a method to *avoid* using sequence-specific primers. That is, the inventors suggested
14 their invention as an *alternative* to specific primer methods such as PCR.

15 49. In all of their drawings, descriptions, and examples included in the '338 patent, the
16 inventors clearly taught that by adding the specificity of a target capture step, scientists could
17 avoid the need to use specific primers and enzymes in the amplification step of a nucleic acid
18 assay.

19 50. I understand that the patent statute requires that the patent set forth enough details
20 to enable a person skilled in the art to make and use the invention, as it is claimed, without
21 requiring more than routine experimentation. It is unclear to me how the '338 patent enables a
22 person of ordinary skill in the art as of December 1987 to use methods that combined target
23 capture and sequence-specific amplification techniques, when no such methods were described in
24 the patent.

25 51. I also have been informed that the patent statute requires that the "written
26 description" of the invention set forth in the specification patent must demonstrate that the
27 inventor(s) had actually invented the invention, *as it is claimed*, when the patent application was
28 filed. The '338 patent does not show that the inventors invented any methods that combined target

1 capture with sequence-specific amplification, and the patent in fact tells those skilled in the art that
2 specific amplification is not necessary when the invention of the patent is employed. Specific
3 amplification cannot, therefore, be a part of the invention.

4 **SUMMARY**

5 52. A person of ordinary skill in the art, reading the '338 patent, would understand the
6 term "amplifying" as used in the claims to mean amplifying with the methods of non-specific
7 amplification described in the patent. Moreover, upon reading the '338 patent, a person of
8 ordinary skill in the art would not have understood the term "amplifying" as used in the claims to
9 mean amplifying by using sequence-specific primers, and/or specific enzymes in methods of
10 sequence-specific amplification.

11 I hereby declare under penalty of perjury under the laws of the United States of America
12 that all statements made herein of my own knowledge are true and that all statements made on
13 information and belief are believed to be true. As discovery in this case is now just beginning, I
14 reserve the right to change my opinion. This declaration was executed by me on this 26th day of
15 April, 2001 at Blacksburg, Virginia.

16 
17 Joseph O. Falkingham, III
18
19
20
21
22
23
24
25
26
27
28